Spire Healthcare backs £1.03bn takeover

Spire Healthcare Group has agreed to be acquired by a consortium of investment funds managed by Toscafund, Three Hills and Ares in an all-cash transaction. The offer is priced at 250 pence per share and values the company’s issued share capital at about £1.03 billion. The board of Spire has recommended that shareholders vote in favour of the deal, describing it as the best available outcome following a comprehensive strategic review of options.

The announcement came shortly before a takeover deadline, following a period in which the group evaluated different strategic and financial alternatives. The agreed cash price was identified as the highest proposal received during this review process. The recommendation reflects both the financial terms and the board’s assessment of the operating environment facing the business.

Spire stated that shareholders representing 53.4% of the company’s issued share capital have already indicated support for the acquisition. This level of backing provides substantial momentum for the proposed transaction ahead of the required shareholder vote. The offer is structured as a cash consideration per share, giving investors the opportunity to realise their holdings at the agreed price of 250 pence.

The consortium of Toscafund, Three Hills and Ares is seeking full control of Spire’s share capital through the transaction. With more than half of shareholders expressing support, the deal has cleared a key threshold of indicative approval, though it remains subject to customary conditions, including formal shareholder and regulatory clearances.

Spire’s board undertook a strategic review before recommending the takeover, assessing the company’s prospects as an independent listed group against alternative outcomes. Chair-designate Debbie White highlighted that the decision to back the acquisition took into account both the progress made in improving care quality and diversifying the business, and the challenges in the wider healthcare sector.

The board pointed to a volatile sector outlook and material cost pressures as important factors in its conclusion. Against this backdrop, the directors determined that the certainty of the cash offer, at the level proposed by the consortium, represents an attractive route for shareholders. The review process also confirmed that no higher proposal was available at the time of the recommendation.

Spire operates 38 hospitals and more than 55 clinics, giving it a significant footprint in the UK independent healthcare market. The group’s network underpins its role in delivering a range of medical and surgical services nationwide. This scale and diversification were referenced as part of the board’s assessment of the company’s position and prospects.

While the transaction terms focus on shareholder value, the board also framed the deal in the context of the group’s ongoing evolution. The emphasis on care quality improvements and a diversified service offering suggests these areas are expected to remain central to Spire’s strategy under new ownership, within the constraints of the broader sector environment.